Efficacy of spirometry in COPD patients with pulmonary hypertension: A study in a tertiary care unit

---

Original Article

Author Details : Chappidi Rajesh Reddy, C Mallikarjuna Reddy*

Volume : 5, Issue : 4, Year : 2020

Article Page : 250-253

https://doi.org/10.18231/j.ijirm.2020.067

Suggest article by email

Get Permission

---

Abstract

Background: Therapy for COPD patients, in particular those with advanced stage, is generally disappointing and frustrating for both the doctors and patient. Of the symptoms, dyspnea is an important and debilitating symptom for which most patient with COPD seek medical attention. For the evaluation of lung function test for pulmonary hypertension, arterial PO2 and FEV1 seem to be most reliable.
Materials and Methods: COPD was diagnosed as per GOLD criteria. Baseline FEV1 was measured by spirometer. The patient then received two puffs of salbutamol. 15 minutes later 3-5 forced expiratory maneuver was repeated and the best FEV1 was recorded. Symptoms Score, and dyspnea grade were correlated with FEV1 both pre and post bronchodilator.
Results: The mean age of the 52 patients was 6010.6 Years. The mean symptom score was 4.07 with SD : 0.81. 7.69% patients were in MRC dyspnea scale grade 1, 21.15% patients had grade 2 dyspnea, 25% patients had grade 3 dyspnea, 40.38% patients had grade 4 dyspnea and 5.76% patients had dyspnea of grade 5. There was a strong significance in the correlation of Symptom scale with Pre bronchodilator % predicted FEV1 and with post bronchodilator % predicted FEV1:
Conclusions: There was a high correlation between dyspnea and pulmonary hypertension measured by percentage predictive value. Spirometry was found to be very useful for the diagnosis and staging of COPD. This could be used in primary diagnosis of patients with COPD.

Keywords: Chronic obstructive pulmonary disease, Pulmonary hypertension, Spirometry.

How to cite : Reddy C R, Reddy C M, Efficacy of spirometry in COPD patients with pulmonary hypertension: A study in a tertiary care unit. IP Indian J Immunol Respir Med 2020;5(4):250-253

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.